Gene therapy for Usher syndrome type 1B vision loss
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This trial tests an experimental gene therapy given as an injection under the retina. It aims to slow or stop vision loss in people with Usher syndrome type 1B, a rare genetic condition that causes both hearing and vision problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of Usher syndrome type 1B caused by a MYO7A gene mutation.
- You cannot have taken part in a gene therapy trial before.
- You must not have been in any other clinical trial for an investigational treatment in the last 6 months.
- You must not have any eye condition that would make the surgery under the retina unsafe.
- You must not have other serious eye or body diseases that could affect the study.
- You must be willing to follow the study rules and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
This early-phase trial tests a gene therapy called AXV-101 for children with vision loss caused by BBS1 genetic mutations. The goal is to see if it can help slow or stop retinal damage.
This Phase 1/2 study tests the safety of putting a gene medicine into the eye for people with vision loss caused by LCA5 gene mutations. It includes a treatment group and a separate group of people who do not receive the gene medicine during the study.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
Hear when a new Usher Syndrome, Type 1B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.